Want to see HK:2315 full AI Analyst Report?
Total Valuation
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has a market cap or net worth of HK$30.75B. The enterprise value is HK$20.54B.
Market CapHK$30.75B
Enterprise ValueHK$20.54B
Share Statistics
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has 110,781,920 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding110,781,920
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 8.49%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)8.49%
Return on Capital Employed (ROCE)0.10
Revenue Per Employee955.51K
Profits Per Employee130.30K
Employee Count1,443
Asset Turnover0.37
Inventory Turnover1.91
Valuation Ratios
The current PE Ratio of Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H is 69.3. Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s PEG ratio is 0.18.
PE Ratio69.3
PS Ratio9.20
PB Ratio5.83
Price to FCF44.91
Price to Operating Cash Flow55.72
PEG Ratio0.18
Income Statement
In the last 12 months, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H had revenue of 1.38B and earned 173.20M in profits. Earnings per share was 0.43.
Revenue1.38B
Gross Profit1.05B
Operating Income278.60M
Pretax Income188.03M
Net Income173.20M
EBITDA419.49M
Earnings Per Share (EPS)0.43
Cash Flow
In the last 12 months, operating cash flow was 411.09M and capital expenditures -273.34M, giving a free cash flow of 137.75M billion.
Operating Cash Flow411.09M
Free Cash Flow137.75M
Free Cash Flow per Share1.24
Dividends & Yields
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.83
52-Week Price Change146.34%
50-Day Moving Average63.37
200-Day Moving Average51.88
Relative Strength Index (RSI)53.08
Average Volume (3m)1.71M
Important Dates
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H upcoming earnings date is Mar 31, 2027, Before Open (Confirmed).
Last Earnings DateAug 27, 2026
Next Earnings DateMar 31, 2027
Ex-Dividend Date―
Financial Position
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H as a current ratio of 2.31, with Debt / Equity ratio of 35.89%
Current Ratio2.31
Quick Ratio2.12
Debt to Market Cap0.03
Net Debt to EBITDA-2.33
Interest Coverage Ratio3.92
Taxes
In the past 12 months, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has paid 14.83M in taxes.
Income Tax14.83M
Effective Tax Rate0.08
Enterprise Valuation
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H EV to EBITDA ratio is 27.91, with an EV/FCF ratio of 41.45.
EV to Sales8.49
EV to EBITDA27.91
EV to Free Cash Flow41.45
EV to Operating Cash Flow31.62
Balance Sheet
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has HK$1.04B in cash and marketable securities with HK$869.00M in debt, giving a net cash position of HK$169.68M billion.
Cash & Marketable SecuritiesHK$1.04B
Total DebtHK$869.00M
Net CashHK$169.68M
Net Cash Per ShareHK$1.53
Tangible Book Value Per ShareHK$5.41
Margins
Gross margin is 77.06%, with operating margin of 20.21%, and net profit margin of 12.56%.
Gross Margin77.06%
Operating Margin20.21%
Pretax Margin13.64%
Net Profit Margin12.56%
EBITDA Margin30.42%
EBIT Margin18.79%
Analyst Forecast
The average price target for Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast48.04%
EPS Growth Forecast166.72%